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Icodextrin is a newly available glucose-free peritoneal dialysis solution that can be used in diabetic patients
with poor glycemic control. It is less readily absorbed from the peritoneal cavity and, hence, has the advantage
of reduced glucose absorption. This new osmotic agent, however, is not metabolically inert. Absorption of
icodextrin can result in accumulation of oligosaccharide metabolites that interfere with some laboratory
tests. We report a patient suffering from spurious hyperglycemia after using this new osmotic agent. Various
mechanisms of hemoglucostix are discussed to provide information to clinicians on one important potential
complication of this new osmotic agent. [Hong Kong J Nephrol 2004;6(2):103–5]
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INTRODUCTION
Diabetes mellitus is the commonest cause of end-stage
renal failure, treated with renal replacement therapy,
in Hong Kong. As 80% of our dialysis population re-
ceive peritoneal dialysis, the management of this dialy-
sis population is a great burden on nephrologists. Poor
sugar control is commonly encountered in daily clinical
practice. We report a diabetic patient treated with peri-
toneal dialysis who had poor glycemic control.
CASE REPORT
A 70-year-old lady who suffered from end-stage renal
disease secondary to diabetic nephropathy presented
to the emergency department for acute retention of urine
and dysuria. She had received peritoneal dialysis for 3
years. Icodextrin-based dialysate (ExtranealTM, Baxter
Healthcare Corp, Deerfield, IL, USA) had been used
for the previous 6 months because of poor ultrafiltra-
tion and high serum glucose concentration. Ultrafiltra-
tion and blood sugar control improved with the use of
icodextrin. Her fasting hemoglucostix readings at home
ranged from 5 to 10 mM. Her diabetes mellitus was
treated with a short-acting sulfonylurea and subcuta-
neous intermediate-acting insulin (MonotardTM, Novo
Nordisk A/S, Bagsvaerd, Denmark).
The patient had very unsatisfactory diabetic control
at her current admission, with immeasurably high he-
moglucostix readings. An extra 6 units of short-acting
insulin were given subcutaneously after blood was
taken for plasma glucose estimation. The laboratory
plasma glucose concentration was 27 mM. The gluco-
meter used in the admission ward was an Accu-Chek
Advantage® (Roche Diagnostics, Basel, Switzerland),
with a measuring range of 0.6–33.3 mM (Table). Blood
glucose control was not improved and repeated hemo-
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glucostix readings 6 hours later were immeasurably
high. Another 6 units of short-acting insulin were given.
The dosage of intermediate-acting insulin was escalated
in view of her poor diabetic control. Two days later,
the patient was advised to bring back her home gluco-
meter for more accurate hemoglucostix monitoring.
The model she used was a Precision QID® (Abbott
Laboratories, Bedford, MA, USA). Unfortunately, she
developed hypoglycemia that night secondary to the
multiple extra doses of short-acting insulin. Her con-
dition improved rapidly after dextrose infusion.
DISCUSSION
Dextrose is used as an osmotic agent in conventional
peritoneal dialysis solutions to effect osmotic ultrafiltra-
tion. Glucose is readily absorbed from the dialysate,
resulting in rapid dissipation of the osmotic gradient
and high blood sugar levels, especially in patients with
diabetes mellitus [1]. Icodextrin, a high-molecular-
weight glucose polymer, is absorbed less readily from
peritoneal dialysate. This results in the advantage of
maintenance of the osmotic gradient after a longer
dwell time in the peritoneum. Little or no free glucose
is liberated within the peritoneal cavity following the
administration of icodextrin and, hence, it is function-
ally a “non-glucose” osmotic agent [2].
After absorption into the systemic circulation via
the lymphatic system, icodextrin polymers are metab-
olized into smaller oligosaccharides by plasma amy-
lases. The predominant metabolites are maltose (2
glucose molecules), maltotriose (3 glucose molecules),
and maltotetraose (4 glucose molecules) [1]. These
metabolites of icodextrin accumulate in the systemic
circulation due to a lack of circulating maltase.
The free reducing group of these icodextrin me-
tabolites can react with certain enzyme systems in the
test kit of some glucometers to produce a falsely ele-
vated reading. Maltose interferes with glucose assays
that utilize the glucose dehydrogenase with coenzyme
pyrroloquinoline quinone (GDH PQQ) system [3]. This
method of measuring glucose concentrations can
significantly overestimate glycemia [4,5]. Wens et al
evaluated discrepancies in six patients treated with
once-daily icodextrin for a minimum of 7 consecutive
days [4]. The overestimation of glycemia by GDH
PQQ-based methods was 3.6 ± 1.4 mmol/L compared
to the reference method (p < 0.01). Oyibo et al evaluat-
ed 25 end-stage renal failure patients treated with ico-
dextrin and demonstrated that only 5% of glucometer
values using the GDH PQQ system fell within 20% of
the corresponding laboratory values [6]. A correction
factor cannot be used because overestimation varies
widely.
In our hospital, 10 (2.6%) of our renal patients on
peritoneal dialysis are currently treated with icodextrin-
based dialysate. Five suffered from ultrafiltration failure
and five from poorly controlled diabetes mellitus. Home
blood glucose monitoring by hemoglucostix is advised
in patients with poorly controlled diabetes. The patient
in this case used a system based on glucose oxidase at
home with no problems, but the situation changed after
the current admission when her blood glucose monitor-
ing was changed to another system in the hospital. Al-
though the effect of icodextrin on glucose testing has
been previously reported, many clinicians remain un-
aware of the problem.
The measurement of plasma glucose level in our
hospital laboratory is also based on a system that detects
the oxidation of glucose molecules specifically (glucose
hexokinase assay, Roche Diagnostics, Mannheim, Ger-
many). Spent icodextrin solution has been sent to the
laboratory to exclude cross-reactivity between other
oligosaccharide molecules and the assay system.
The Table lists the common glucometer models that
we usually introduce to our diabetic patients. Other hos-
pitals may have their own list. We suggest that clini-
Table. Common glucometers used in Hong Kong
Brand name Manufacturer Enzyme system Measuring range (mM)
Accu-Chek Advantage Roche Diagnostics* Glucose dehydrogenase 0.6–33.3
MediSense Optium Abbott Laboratories† Glucose dehydrogenase 1.1–27.8
Ascensia Elite Bayer Diagnostics‡ Glucose oxidase 1.1–33.3
Ascensia Entrust Bayer Diagnostics‡ Glucose oxidase 3.3–23.7
Medisense Precision QID Abbott Laboratories† Glucose oxidase 1.1–33.3
OneTouch Ultra Johnson & Johnson§ Glucose oxidase 1.1–33.3
SmartScan Johnson & Johnson§ Glucose oxidase 1.1–33.3
SureStep Johnson & Johnson§ Glucose oxidase 1.0–27.8
*Roche Diagnostics, a division of F. Hoffmann-La Roche Ltd, Basel, Switzerland; †MediSense Inc, Bedford, MA, USA; ‡Bayer HealthCare
LLC, Tarrytown, NY, USA; §Johnson & Johnson Company, Milpitas, CA, USA.
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cians refer to the product inserts included in the test
strip packages or contact the manufacturers. Education
of medical and nursing staff about the overestimation
of blood glucose concentrations by GDH PQQ-based
glucometers in peritoneal dialysis patients treated with
icodextrin is important. Glucose oxidase-based gluco-
meters should be available in the wards for monitor-
ing hemoglucostix in this group of patients should
they be admitted to hospital.
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